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Abstract 
Background: Occurrence and progression of hepatocellular carcinoma (HCC) are associated with hepatitis B virus 
(HBV) infection. miR‑1269b is up‑regulated in HCC cells and tissues. However, the regulation of miR‑1269b expression 
by HBV and the mechanism underlying the oncogenic activity of miR‑1269b in HCC are unclear.
Methods: Reverse transcription quantitative PCR (RT‑qPCR) was used to measure the expression of miR‑1269b and 
target genes in HCC tissues and cell lines. Western blot analysis was used to assess the expression of miR‑1269b 
target genes and related proteins. Using luciferase reporter assays and EMSA, we identified the factors regulating the 
transcriptional level of miR‑1269b. Colony formation, flow cytometry and cell migration assays were performed to 
evaluate the phenotypic changes caused by miR‑1269b and its target in HCC cells.
Results: We demonstrated that the expression levels of pre‑miR‑1269b and miR‑1269b in HBV‑positive HepG2.2.15 
cells were dramatically increased compared with HBV‑negative HepG2 cells. HBx was shown to facilitate translocation 
of NF‑κB from the cytoplasm to the nucleus, and NF‑κB binds to the promoter of miR‑1269b to enhance its transcrip‑
tion. miR‑1269b targets and up‑regulates CDC40, a cell division cycle 40 homolog. CDC40 increases cell cycle progres‑
sion, cell proliferation and migration. Rescue experiment indicated that CDC40 promotes malignancy induced by 
miR‑1269b in HCC cells.
Conclusion: We found that HBx activates NF‑κB to promote the expression of miR1269b, which augments CDC40 
expression, contributing to malignancy in HCC. Our findings provide insights into the mechanisms underlying HBV‑
induced hepatocarcinogenesis.
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Background
HCC is the second most common causes of cancer death 
in the world, with 0.8 million deaths per year worldwide 
[1]. Chronic HBV infection is closely associated with the 
initiation and development of HCC. Approximately 50 % 
of all HCC cases are linked to HBV chronic infection 
globally [2]. The mechanisms of HBV-induced malig-
nant transformation are not completely clear, however, 
accumulated evidence has indicated that the HBV X pro-
tein acts as a multifunctional regulator in carcinogen-
esis of HCC [3, 4]. HBx is the smallest protein (17 kDa) 
encoded by HBV [5]. Numerous studies have shown that 
HBx plays a crucial role in the development of HBV-
related HCC. The HBx protein promotes cellular prolif-
eration and invasion through several mechanisms [6–8]. 
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been confirmed to function as a transcriptional activa-
tor. The HBx protein does not bind to DNA but interacts 
directly with several transcription factors to either sup-
press or activate them, for example, repression of p53 [9, 
10] and activation of C/EBP [11], AP-1 [12], AP-2 [13], 
and STAT3 [14]. The transcription factor NF-κB was 
identified as the first HBx-responsive motif that could be 
activated by HBx [13]. Sequential reports demonstrated 
that HBx modulates the expression of various NF-κB tar-
get genes [14–16]. However, the molecular mechanisms 
of HBx-induced malignancy in HCC are complicated and 
far from being fully understood.
The NF-κB transcription factor belongs to the proto-
oncogene family Rel, which is composed of five proteins, 
p50 (NF-κB1), p52 (NF-κB2), RelA (p65), RelB and c-Rel 
(Rel). Two of these proteins can form a homodimeric or 
heterodimeric transcription factor complex, and all of 
them possess DNA binding and protein dimerization 
activity because of their N-terminal domain. Known 
as the Rel homology (RH) domain [17]. Except for the 
NF-κB p65/c-Rel heterodimer, the NF-κB dimers bind 
to specific DNA elements with a consensus sequence of 
5′-GGGRNYYYCC-3′ (R-unspecified purine; N-any base; 
Y-unspecified pyrimidine) called the κB sites. NF-κB 
usually refers to the p50/p65 heterodimer because of its 
high expression levels in somatic cells, and it binds vari-
ous κB sites. NF-κB needs to be translocated from the 
cytoplasm to the nucleus by an activator, for example, 
tumour necrosis factor alpha (TNF-α) can be an activator 
of NF-κB and positively regulates NF-κB import into the 
nucleus.
MicroRNAs (miRNAs) are small non-coding RNAs 
that are highly conserved and can up- or down-regulate 
the expression of their target genes [18, 19]. miRNAs may 
function as tumor suppressors or oncogenes in various 
cancers [20]. miR-1269 has been reported to be an onco-
gene in HCC cells, and its expression level is substantially 
higher in HCC tissues than in non-cancerous liver tissues 
[21, 22]. miR-1269 is also known as miR-1269a or miR-
1269b, which share the same mature sequence, but they 
are derived from chromosomes 4 and 17 respectively. 
Whether HBV infection influences the expression of 
miR-1269a or miR-1269b is unknown.
In this study, we found that the HBx protein activates 
miR-1269b expression by facilitating the nucleus translo-
cation of NF-κB from the cytoplasm in HCC. The precur-
sor of miR-1269a and miR-1269b was detected in HepG2 
and HepG2.2.15 cells by reverse transcription qPCR (RT-
qPCR). Mature miR-1269 and pre-miR-1269b, but not 
the pre-miR-1269a, were highly expressed in HepG2.2.15 
cells. Thus, up-regulated miR-1269b and pre-miR-1269b 
are related to HBV. Furthermore, we found that miR-
1269b targets and enhances CDC40 expression, a splicing 
factor involved in cell cycle control [23, 24], which medi-
ates the effects of miR-1269b on cell growth, cell cycle 
and cell migration in HCC cells. These findings reveal a 
new pathway of HBx/NF-κB/miR-1269b/CDC40 that 
contributes to tumorigenesis in HBV-associated HCC.
Methods
Cell lines, cell cultures and cell transfection
The human hepatocarcinoma cell lines HepG2 and 
SMMC-7721 (HBV-negative) were purchased from the 
American Type Culture Collection. HepG2.2.15 (HBV-
positive) cells were obtained from the Shanghai Second 
Military Medical University. HepG2 and HepG2.2.15 
cells were cultured in MEM-α (HyClone, China) con-
taining 10 % FBS (Gibco, USA), 100 U/ml penicillin and 
streptomycin, and 5 mmol/l glutamine. SMMC-7721 was 
cultured in RPMI-1640 (HyClone, China) supplemented 
with 100  U/ml penicillin and streptomycin. Cells were 
incubated in a humidified 37 °C incubator with 5 % CO2.
Cell transfection was performed using the Lipo-
fectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions.
Plasmid construction
A pri-miR-1269b PCR product (see primers below) was 
inserted into the pcDNA3 vector between its BamHI and 
EcoRI sites, and 2′-O-methyl-modified antisense oligonu-
cleotides for miR-1269b (ASO-miR-1269b) and scram-
ble control oligonucleotides (ASO-NC) were purchased 
from the GenePharma (Shanghai, China). The promoter 
of pri-miR-1269b, which contained the predicted NFκB1 
binding sites (pMiR-1269b-luc), and a promoter of pri-
miR-1269b from which the predicted NFκB1 binding 
sites were removed (pMiR-1269b-luc-mut) were cloned 
into the XholI-EcoRI and KpnI-EcoRI sites of the pGL3-
Basic-luc+ vector, respectively. The CDC40 gene was 
amplified from a cDNA derived from HepG2 cells and 
cloned into the pcDNA3/HA tag vector between its 
EcoRI and XhoI sites. CDC40 knockdown primers were 
synthesized from GenePharma (Shanghai, China). The 
two strands were annealed and then cloned into the 
BamHI and HindIII sites of the pSilencer2.1-neo vector 
(Ambion, Austin, TX). The fragments of CDC40 3′UTR 
containing the miR-1269b binding site and its mutated 
form were cloned into pcDNA3-EGFP vectors between 
the BamHI and EcoRI sites. The sequences of all primers 
and oligos are shown in Table 1.
RNA extraction and reverse transcription quantitative PCR 
(RT‑qPCR)
Total RNAs were extracted from HepG2 and SMMC-
7721 cells by using TRIzol reagent (Invitrogen, Carlsbad, 
CA). RT-qPCR assays were performed as described in a 
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previous study [25]. The primers used for RT-q PCR are 
listed in Table 2.
Luciferase reporter assay
SMMC-7721 cells were seeded into 48-well culture 
plates. Three wells were seeded per group. A total of 
500 ng of pGL3-Ctrl-luc+ vector, 500 ng of pMiR-1269b-
luc or 500  ng of pMiR-1269b-luc-mut and 50  ng of the 
pRL-TK plasmid were co-transfected into the cells of 
each well for 24  h. A Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI) was used to analyze 
the experimental results. The rest of the luciferase activ-
ity tests were cultured in the same way for 24 h, the cells 
were treated with or without TNF-alpha.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a LightShift Chemilumines-
cent EMSA Kit (Thermo) according to the manufactur-
er’s protocol. The 3′-end-biotin-labeled double-stranded 
DNA and the unlabeled DNA (dsDNA) oligonucleotide 
probes or competitors (GenePharma, Shanghai, China) 
containing an NF-κB-binding site corresponded to the 
sequence 5′-GCCAGACCCGGGACCCTCCTTTTGAG 
GC AC-3′ (probe 1) or 5′-TAGCTGAGAGGGTGTTTCC 
AAAAGA GACCA-3′ (probe 2). DNA binding com-
plexes were formed in 20-μl samples containing 20 fmol 
biotin-labeled oligonucleotides, 10  μg nuclear extracts, 
2 μl 10 × binding buffer, 1 μl 50 % glycerol, 5 mM MgCl2, 
and 0.05  % NP-40. For competitor EMSA, 20- or 100-
fold dilutions of unlabeled oligonucleotides were added 
prior to the addition of the labeled probe. The samples 
were run on 6  % non-denaturing polyacrylamide gels 
with 0.5×TBE buffer and then transferred to a nylon 
membrane at 380 mA for 40 min. The membranes were 
crosslinked at 120 mJ/cm2 using a commercial UV-light 
apparatus for 5  min. A chemiluminescent detection 
method was performed where in a luminal/enhancer 
solution and a stable peroxide solution were used as 
described by the manufacturer.
Western blot analysis
Total protein was extracted from 24 to 48 h post-trans-
fected cells in RIPA lysis buffer. Isolated proteins were 
separated using 10 or 12  % SDS-PAGE and then elec-
troblotted onto PVDF membranes. The primary anti-
bodies used in this study included NF-κB, CENPA, 
E-cadherin, vimentin and GAPDH, which were obtained 
from Saier Co. (Tianjin, China). The CDC40 antibody and 
the secondary goat anti-rabbit antibody were obtained 
from Sigma and used according to standard protocols.
Fluorescence assay
HepG2 and SMMC-7721 cells were cultured in 24-well 
culture plates at a density of 1 × 104 or 3 × 104 cells per 
well in MEM-α or RPMI-1640 medium containing 10 % 
fetal bovine serum (FBS). Cells were cultured at 37  °C 
for 24  h before transfection. Cells were co-transfected 
with the EGFP reporter constructs and miRNA expres-
sion construct. After 48  h incubation, the cells were 
collected and lysed in RIPA buffer. The RFP expression 
vector pDsRed2-N1 was used as the internal control. 
The intensities of both EGFP and RFP fluorescence were 
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detected using an F-4500 fluorescence spectrophotom-
eter (Hitachi, Tokyo, Japan). All of the experiments were 
repeated three times.
Colony formation assay
Transfected HepG2 and SMMC-7721 cells were seeded 
into 12-well plates at 300 cells and 800 cells per well. 
After 7 or 14 days, when more than 50 proliferating cells 
had turned into a colony, the colonies were stained with 
crystal violet to observe and count the cells. The colony 
formation rate (colony number)/(seeded cell number) 
was determined.
Flow cytometric analysis
At 24  h post-transfection, HepG2 and SMMC-7721 
cells were seeded into 6-well plates in complete culture 
medium for growth and proliferation assay. The medium 
was then exchanged and the cells were cultured under 
serum-starved conditions for 48  h. The cells were then 
returned to complete medium and cultured for 24  h. 
Cells were re-suspended in 95  % ethanol after centrifu-
gation, incubated at −20 °C overnight, washed with PBS 
and suspended in a solution containing propidium iodide 
(PI) staining buffer (PBS, 50 μg/ml PI, 0.1 mg/ml DNase-
free RNase) for 30 min on ice. Cells were analyzed using 
a FACS Calibur flow cytometer (DB Biosciences) and 
FlowJo software (DB Biosciences).
Cell migration assay
The migratory ability of HepG2 and SMMC-7721 cells 
was measured using transwell migration assays. After 
24 h of transfection, cells were placed in 200 μl of RPMI-
1640 or MEM-α without FBS and seeded in Transwell 
chambers (pore size, 8 μm; Corning Costar, Cambridge, 
MA, USA), which were placed into 24-well culture plates 
that were loaded with 20 % FBS RPMI 1640 or MEM-α 
(600 μl). The cells were cultured in 37 °C humidified incu-
bator for 24 h, and the chambers were removed, fixed and 
stained after the upper surface was wiped to remove the 
non-migrated cells. Images were captured using a NISE-
lements F 3.0 System (Nikon, Tokyo, Japan). Five random 
visual fields per transwell were analyzed for calculations. 
Each assay was performed three times.
Results
HBx promotes transcription of pri‑miR‑1269b via activating 
NF‑κB
To explore whether the upregulation of miR-1269 in 
HBV-related HCC was derived from miR-1269a or miR-
1269b, we performed RT-qPCR assay. Our data showed 
that the expression level of miR-1269 in HBV-produced 
cell line HepG2.2.15 is higher than that of HepG2 cells 
with HBV negative, and pre-miR-1269b level was signifi-
cantly higher than pre-miR-1269a level in HepG2.2.15 
cells compared with HepG2 cells (Fig. 1a), which suggest 
miR-1269 was induced by HBV. To determine whether 
HBx protein participates in this process, we ectopic 
expressed HBx in HBV-negative HCC cells. As shown in 
Fig. 1b, ectopic expression of HBx in HBV-negative HCC 
cells (HepG2 and SMMC-7721) increased the expression 
levels of pre-miR-1269b and miR-1269b. Since HBx pro-
tein does not bind to DNA sequence, a transcription fac-
tor that exactly controlled the expression of miR-1269b 
was taken into consideration. HBx can be a transcrip-
tion activator of many host factors and NF-κB could be 
notably activated through the relocation from cytoplasm 
into nucleus by interacting with HBx (29). We detected 
nuclear NF-κB in HepG2 with HBx plasmid transfection, 
Table 2 Primers used in qRT-PCR
Name Primer sequence
U6 RT primer 5′‑GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATATGGAAC‑3′
miR‑1269b RT primer 5′‑GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCCAGTAGC‑3′
U6 forward 5′‑TGCGGGTGCTCGCTTCGGCAGC‑3′
U6 reverse 5′‑CCAGTGCAGGGTCCGAGGT‑3′
miR‑1269b forward 5′‑ TGCGCTGGACTGAGCCATGC‑3′
pre‑miR‑1269b‑qPCR‑S 5′‑CAGGCTGGGAGAAAGACC‑3′
pre‑miR‑1269b‑qPCR‑AS 5′‑GGAAGTTGGCTCACATAATC‑3′
pre‑miR‑1269a‑qPCR‑S 5′ TGGATTGCCTAGACCAGGG 3′
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Fig. 1 The level of miR‑1269b was increased in HBV‑HCC cells by pre‑miR‑1269b, which was up‑regulated by HBx‑activated NF‑κB. a The relative 
expression levels of miR‑1269b, pre‑miR‑1269b and pre‑miR‑1269a in HepG2 and HepG2.2.15 cells were detected using real‑time PCR. b The relative 
expression level of miR‑1269b in HepG2 and SMMC‑7721 cells transfected with pFLAG or pFLAG‑HBx. c HBx promoted the nuclear translocation of 
NF‑κB nucleus, as confirmed by western blot analysis. d The relative levels of miR‑1269b and pri‑miR‑1269b were up‑regulated in cells transfected 
with NF‑κB compared to their levels in cells that were transfected with the control vector. All error bars indicate the mean standard deviation based 
on three independent experiments. *p < 0.05, **p < 0.01
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NF-κB content was evidently increased compared with 
the control vector (Fig.  1c). Meanwhile, overexpression 
of NF-κB induced miR-1269b and pre-miR-1269b expres-
sion in HepG2 and SMMC-7721 cells (Fig.  1d). Alto-
gether, these results suggested that the higher expression 
of miR-1269b in HBV positive HCC cells may be caused 
by NF-κB which strongly activated by HBx protein.
NF‑κB binds to the promoter of miR‑1269b to activate its 
expression
To determine whether NF-κB promotes transcription 
of miR-1269b, we predicted the promoter of miR-1269b 
by utilizing bioinformatics website Promoter 2.0 Predic-
tion Server (http://www.cbs.dtu.dk) and Promoter Scan 
(http://www-bimas.cit.nih.gov). The miR-1269b pro-
moter was cloned in pGL3-basic vector (pMiR-1269b-
luc) (Fig.  2a). Bioinformatic analysis indicated that 
miR-1269b promoter contains two binding sites of NF-κB 
(5′-GGGRNYYYCC-3′) (http://www.genomatix.de) 
(Fig.  2a). Luciferase reporter assay showed that luciferase 
activity in HepG2.2.15 cells was significantly higher than 
that in HepG2 cells (Fig.  2b). We constructed a mutant 
promoter plasmid (pMiR-1269b-luc-M) that deleted the 
region within NF-κB binding sites. As shown in Fig.  2c, 
pMiR-1269b-luc-M still possessed activity but dramatically 
decreased compared with pMiR-1269b-luc in non-NF-κB-
activated SMMC-7721 cells. Next, overexpression of NF-κB 
or activation of NF-κB by low concentration of TNF-alpha 
(TNF-α) increased the pMiR-1269b-luc activity, but not 
affect the pMiR-1269b-luc-M activity in SMMC-7721 cells 
(Fig. 2d). To determine the effect of HBx on the promoter 
activity of miR-1269b, pMiR-1269b-luc and HBx or HBV 
expression plasmid, pHBV1.3 containing 1.3 copy of HBV 
genome in pUC18) [26] were co-transfected into HBV-neg-
ative HCC cells. Both HBx and pHBV1.3 plasmid induced 
miR-1269b promoter activity, but didn’t affect the activ-
ity of miR-1269b promoter mutant (Fig. 2e). Furthermore, 
luciferase reporter assay also demonstrated that HBx-
induced miR-1269b expression was enhanced by overex-
pression NF-κB (Fig.  2f). To verify the direct interaction 
between NF-κB and miR-1269b promoter, EMSA assay was 
performed using biotin-labeled NF-κB consensus oligonu-
cleotides in the miR-1269b promoter (−691 to −681) as 
probe 1, and miR-1269b promoter (−194 to −184) as probe 
2. Nuclear extracts were incubated with probe1 or probe 
2 or in the presence of two unlabeled, wild-type NF-κB 
binding probes. The wild-type NF-κB consensus oligonu-
cleotides showed strong competition in combination with 
NF-κB (Fig. 2g). These results indicate that NF-κB directly 
activates the transcription of miR-1269b and HBx indi-
rectly activates the transcription of miR-1269b in NF-κB 
dependent manner.
miR‑1269b promotes proliferation, cell cycle and migration 
in HCC cell lines
The proliferation potential of miR-1269b was analyzed 
in HepG2 and SMMC-7721 cells transfected with miR-
1269b overexpression (pri-miR-1269b) and miR-1269b 
antisense oligonucleotides (ASO-miR-1269b). Colony 
formation assay showed that overexpression of miR-
1269b significantly promoted, but ASO-miR-1269b 
repressed cell proliferation in HepG2 and SMMC-7721 
cells (Fig. 3a). Cell cycle analyses demonstrated that pri-
miR-1269b enhanced, whereas ASO-miR-1269b delayed 
the transition of G1 to S/M phase (Fig.  3b). Transwell 
assay was applied to evaluate the effects of miR-1269b on 
migration in HCC cells. Cell migration was significantly 
enhanced in HepG2 and SMMC-7721 cells transfected 
with miR-1269b, while repressed in the cells transfected 
with ASO-miR-1269b compared to their respective con-
trol groups (Fig. 3c). The increase of cell migration abil-
ity was usually associated with EMT. The main protein 
markers of EMT including E-cadherin and vimentin 
were examined by western blot. As shown in Fig.  3d, 
overexpression of miR-1269b decreased E-cadherin and 
increased vimentin level, but ASO-miR-1269b resulted 
in an opposite effect, which was corresponded to pheno-
typic changes (Fig. 3d). Taken together, these results indi-
cate that miR-1269b enhances oncogenic activity in HCC 
cells.
(See figure on next page). 
Fig. 2 NF‑κB binds directly to the miR‑1269b promoter and up‑regulates its transcription. a The human miR‑1269b genomic locus. The predicted 
promoter of miR‑1269b, which contains two putative binding sites for NF‑κB (pMiR‑1269b‑luc), and the mutant of miR‑1269b promoter that does 
not contain NF‑κB binding sites (pMiR‑1269b‑luc‑M) are shown. b miR‑1269b promoter‑induced luciferase activity was increased in HepG2.2.15 
cells compared to HepG2 cells. c The relative luciferase activity induced by the miR‑1269b promoters constructed with or without NF‑κB bind‑
ing sites and the control vector in SMMC‑7721 cells. d The effect of NF‑κB (left) and TNF‑α (right) on pMiR‑1269b‑luc and pMiR‑1269b‑luc‑M in 
SMMC‑7721 cells. e SMMC‑7721 cells were co‑transfected with pMiR‑1269b‑luc and pMiR‑1269b‑luc‑M with puc18/HBV1.3, pFLAG/HBx(HBx) and 
the control vector, and luciferase activity was then detected after 24 h of transfection. f SMMC‑7721 cells were cotransfected with pMiR‑1269b‑luc 
and pcDNA3 or HBx or NF‑κB or both HBx and NF‑κB. After 24 h, luciferase activity was analyzed. g EMSA to determine the DNA‑binding activity of 
NF‑κB using two substrates (probe 1 and probe 2). The results are shown as the mean ± SD of three experiments that were performed in duplicate. 
*p < 0.05, **p < 0.01
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miR‑1269b enhances CDC40 expression by binding its 
3′UTR in HCC cell lines
miRNAs generally functions as a regulator of gene 
expression by binding to the mRNA 3′UTR. Therefore 
we searched the potential target genes of miR-1269b 
using bioinformatics algorithms including TargetScan 
and miRBase Targets. Finally we chose CDC40 as a can-
didate target of miR-1269b because it regulates cell cycle 
progress and its impact in cancer cells was unclear. The 
miR-1269b binding site in the CDC40 mRNA 3′UTR 
is shown in Fig.  4a. To establish regulative relations 
between miR-1269b and CDC40, RT-qPCR and western 
blot assay were applied. As shown in Fig.  4b, it is sur-
prised that CDC40 mRNA and protein expression level 
were up-regulated by overexpression of miR-1269b but 
down-regulated when miR-1269b was blocked by ASO 
in both HepG2 and SMMC-7721 cells. In addition, EGFP 
reporter assay also showed that overexpression of miR-
1269b increased, but ASO-miR-1269b decreased fluo-
rescence intensities, however, the mutated form (Fig. 4a) 
of 3′UTR binding site in CDC40 mRNA abolished the 
change of fluorescence (Fig. 4c). The results indicate that 
miR-1269b directly targets CDC40 and enhanced CDC40 
expression in HCC cells.
CDC40 promotes proliferation, cell cycle and migration 
and mediates promotion of malignancy induced 
by miR‑1269b in HCC cell lines
Cell proliferation and transwell assays were applied 
to elucidate the effects of CDC40 on of HCC cells. 
As shown in Fig.  5a, b, colony formation and cell cycle 
assays showed that CDC40 overexpression significantly 
enhanced, while knockdown of CDC40 by shRNA 
suppressed the growth and proliferation capacity in 
HepG2 and SMMC-7721 cells. Meanwhile, transwell 
assay showed that overexpression of CDC40 possessed 
stronger influence on migration, which can be impaired 
by reducing expression of CDC40 in HepG2 and SMMC-
7721 cells (Fig.  5c). CDC40 also promoted EMT, which 
was consistent with change of the essential EMT protein 
markers. As shown in Fig.  5d, CDC40 overexpression 
promoted, but knock down of CDC40 repressed vimen-
tin levels, but E-cadherin expression levels had oppositely 
changed by western blot assay. These results indicate that 
CDC40 promotes the tumorigenic activities in HCC cells.
We have evidenced that miR-1269b up-regulates 
CDC40 expression and both CDC40 and miR-1269b pos-
sess the similar effect on malignancy in HCC cells. Thus 
it is necessary to verify the effect of miR-1269b on pro-
liferation and migration was mediated by up-regulating 
CDC40 expression in HCC cells. Rescue experiments 
were performed in following approaches. Colony forma-
tion and cell cycle assays indicated that overexpressing 
CDC40 could reverse the inhibitory effect of the ASO-
miR-1269b on proliferation in HepG2 and SMMC-7721 
cells (Fig.  6a, b). Transwell migration analysis showed 
that the promoting effects of CDC40 on migration were 
abrogated when ASO-miR-1269b was co-transfected 
(Fig.  6c). Meanwhile, changes of EMT protein mark-
ers induced by miR-1269b were reversed by modulation 
of CDC40 expression levels in HepG2 and SMMC-7721 
cells (Fig. 6d). Taken together, these results indicate that 
CDC40 promotes HCC cells proliferation and migration, 
and mediated the oncogenic activities induced by miR-
1269b in HCC cells.
Discussion
MiR-1269 is significantly up-regulated in HCC tissues 
and cell lines and promotes HCC growth by suppressing 
the FOXO1 gene [21, 22]. However, the mechanism of 
miR-1269b up-regulation has not been clarified. Because 
most HCC patients are HBV positive, we hypothesized 
that up-regulation of miR-1269 may be induced by HBV 
infection. As expected, our results indicated that miR-
1269 was highly expressed in HBV-positive hepatoma 
HepG2.2.15 cells compared with the HBV-negative 
HepG2 and SMMC-7721 cells. Bioinformatics analy-
sis showed that miR-1269 has two original transcripts, 
pre-miR-1269a located on chromosome 4 and pre-miR-
1269b located on chromosome 17. To determine which 
precursor or whether both are induced by HBV infec-
tion, RT-qPCR was performed to detect the precursors 
of miR-1269a and miR-1269b. Our results indicated that 
miR-1269 and pre-miR-1269b, but not pre-miR-1269a, 
were highly expressed in HepG2.2.15 cells compared 
with the parental HepG2 cells. Additionally, to determine 
(See figure on previous page.) 
Fig. 3 High expression levels of miR‑1269b promoted the proliferation and migration of HepG2 and SMMC‑7721 cells in vitro. a HepG2 and 
SMMC‑7721 cells were transfected with pcDNA3/pri‑miR‑1269b, ASOmiR‑1269b or a negative control vector in 24‑well plates and then seeded in 
12‑well plates. The number of colonies was counted at 2 weeks after seeding. b Cell cycle progression was analyzed in HepG2 and SMMC‑7721 cells 
using flow cytometry. The chart shows the population of cells that were in G1‑, S‑ and G2/M‑phase. c Transwell migration assays were performed 
to detect the migratory capacity of HepG2 and SMMC‑7721 cells transfected with the same vectors. d The influence of miR‑1269b on the protein 
levels of the EMT‑associated molecules E‑cadherin and vimentin were measured using western blot analysis. All error bars indicate the means ± SDs. 
All experiments were repeated at least three times. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Fig. 4 miR‑1269b directly targets the 3′UTR of CDC40. a The predicted binding sites for miR‑1269b in the 3′UTR of CDC40 and the induced muta‑
tions in the binding sites are shown. b qRT–PCR (left) and representative Western blot analysis (right) of CDC40 levels in HepG2 and SMMC‑7721 
cells transfected with the control vector or ASO‑nc vs miR‑1269b or ASO‑miR1269b‑transduced cells. c Luciferase reporter assays were performed 
in HepG2 and SMMC‑7721 cell lines that were co‑transfected with miR‑1269b in the presence of CDC40 3′UTR (top). In the controls, the mutated 
3′UTR sequences were included (bottom). Columns, mean ± SD of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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whether HBx activates the promoter of miR-1269b, we 
co-transfected a miR-1269b vector and HBx or HBV 
expression plasmid pHBV1.3 containing 1.3 copies of 
the HBV genome in pUC18 [26] into HBV-negative HCC 
cells. Overexpression of HBx induced miR-1269 and 
pre-miR-1269b in HBV-negative HepG2 and SMMC-
7721 cells. Thus, we concluded that the HBV infection-
induced expression of miR-1269 is due to the activation 
of miR-1269b expression.
Next, we determined how the HBV infection induced 
miR-1269b expression. The HBV X protein plays an 
important role in HBV-induced HCC, NF-κB could be 
significantly activated by HBx [27] and is involved in 
tumor progression due to its transcriptional regulation 
of various functional genes and miRNAs [8, 28]. Here, 
we revealed that the HBx protein promoted miR-1269b 
expression. Previous reports have shown that the HBx 
protein activates NF-κB by facilitating translocation of 
NF-κB from the cytoplasm into the nucleus [13–16]. 
Therefore, we hypothesized that the activation of NF-κB 
by the HBx protein may induce miR-1269 expression. 
Our data indicated that the promoter of miR-1269b was 
activated by HBx and NF-κB using luciferase reporter 
assays, and mutation of the predicated NF-κB binding 
sites in the miR-1269b promoter abolished the luciferase 
activity. EMSA assays confirmed the direct interactions 
Fig. 5 CDC40 promotes cell proliferation and migration, which is regulated by miR‑1269b. a Colony formation assays were performed to test the 
influence of CDC40 on proliferation in HepG2 and SMMC‑7721 cells. b Cell cycle progression in the transfected cells was analyzed using flow cytom‑
etry. The chart shows the populations of cells in the different phases of the cell cycle. c Transwell migration assays were performed to detect the 
effect of CDC40 on the migration of HepG2 and SMMC‑7721 cells. d The influence of CDC40 on the protein levels of the EMT‑associated molecules 
E‑cadherin and vimentin was determined using western blot analysis. Cells were transfected 48 h before proteins were harvested. Error bars indicate 
the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 6 Overexpression of CDC40 abrogated the repression of the phenotypes induced by ASO‑miR‑1269b in HepG2 and SMMC‑7721 cells. a 
Colony formation rates. b Cell cycle progression. c Migratory ability. d Corresponding levels of the EMT protein markers E‑cadherin and vimentin. 
Error bars indicate the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001
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between NF-κB and the predicted binding sites in the 
miR-1269b promoter region. Thus, we conclude that 
the HBx protein promotes miR-1269b expression in a 
NF-κB-dependent manner.
miR-1269b promoted cell proliferation, cell cycle and 
migration in HepG2 and SMMC-7721 cells and func-
tioned as an oncogene in HCC cells. Because the effects 
of miRNAs are mediated by its targets, bioinformatics 
analysis identified CDC40 as a candidate target of miR-
1269b. Using EGFP reporter assays, as well as RT-qPCR, 
western blot analysis and a series of rescue experiments, 
we confirmed that CDC40 was up-regulated by miR-
1269b and a functional target of miR-1269b in HCC 
cells. CDC40 has been associated with the spliceosome, 
which regulates pre-mRNA splicing [29, 30], and was 
also linked to cell cycle control [23, 24]. CDC40 exhibits 
a delayed G1/S transition and mutated form causes cell 
cycle arrest at the G2/M stage [24, 31]. However, except 
for one report showing CDC40 as a target of miR-378 in 
colorectal cancer [32], the correlation between CDC40 
and tumor malignancy has not been investigated.
In the present study, CDC40 was shown to enhance cell 
growth, cell cycle progression and migration in HepG2 
and SMMC-7721 cells by gain- and loss-of-function 
analysis. Migration is generally associated with can-
cer metastasis, while EMT plays a crucial role in cancer 
metastasis in HCCs [33]. E-cadherin belongs to a family 
of transmembrane glycoproteins, which are responsible 
for calcium-dependent cell-to-cell adhesion and loss of 
E-cadherin contributes to the cell migration. Meanwhile, 
vimentin is a major protein of the intermediate filament 
family and has also been recognized as a marker for EMT. 
In EMT progression, the epithelial differentiation marker 
E-cadherin is down-regulated, and the mesenchymal 
marker vimentin is up-regulated. In our study, we showed 
that CDC40 could enhance the HCC cell migration via 
ablation of E-cadherin and enhancement of vimentin. 
Moreover, phenotypic rescue experiments demonstrated 
that CDC40 at least partially mediated the promotion of 
the oncogenic activities induced by miR-1269 in HCC 
cells. However, the mechanism by which miR-1269b up-
regulates CDC40 expression needs to be elucidated.
Conclusion
Our finding revealed that HBx protein facilitates NF-κB 
to import into nucleus, resulting in activation of miR-
1269b expression. Upregulation of miR-1269b enhances 
CDC40 protein level by binding its 3′UTR, which pro-
motes the growth and migration in HCC cells. Thus, our 
results presented a novel pathway of HBx/NF-κB/miR-
1269b/CDC40 (Fig. 7) in tumorigenesis in HBV-positive 
HCC and also may provide new potential biomarkers of 
clinical study in HCC.
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Fig. 7 The signaling pathway by which HBx‑induced miR‑1269b 
facilitates proliferation and migration in HBV‑positive HCC cells
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